Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of the anticancer drug olaparib, a CYP3A-substrate, has the potential to reduce PK variability, side effects and financial burden associated with this drug. Afte...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Wietske Kievit, Marjolijn J.L. Ligtenberg, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine, Nielka P. van Erp
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-06-01
Serija:	Contemporary Clinical Trials Communications
Teme:	Clinical trial Olaparib Cobicistat Pharmacokinetic boosting Non-inferiority
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2451865425000511
Oznake:	Označite Brez oznak, prvi označite!